frontMIND: A phase III, randomized, double-blind study of tafasitamab plus lenalidomide plus R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
JOURNAL OF CLINICAL ONCOLOGY（2022）
关键词
ABCL, tafasitamab, lenalidomide, DLBCL, frontMIND, R-CHOP, Phase III
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要